Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Artificial Intelligence UCITS ETF 21.04.2026 FTAI IE000YIQZ0H6 200,002.00 USD 5,091,676.26 25.458  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Alerian Disruptive Technology Real Estate UCITS ETF 21.04.2026 LANDXEN.LN IE000C75IMX8 15,878.00 USD 318,856.53 20.082  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF- June 21.04.2026 MJUN LN IE000CO3P697 150,002.00 USD 3,767,686.25 25.118  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Alerian Disruptive Technology Real Estate UCITS ETF 21.04.2026 LANDXN.LN IE000RN036E0 34,035.00 USD 749,188.13 22.012  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - December 21.04.2026 QDEC.LN IE000GAKWFA7 450,002.00 USD 10,518,775.27 23.375  ...

MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for DMX-1001 (oral noribogaine), a novel neuroplastogen therapeutic for the treatment of alcohol use disorder (AUD). The company recently completed a multiple ascending dose (MAD) clinical trial of DMX-1001 in healthy volunteers. Results from...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Europe Infrastructure UCITS ETF 21.04.2026 FTEI.LN IE000TIZ5AP4 200,002.00 EUR 4,189,301.23 20.946  ...

JASPER, Ind.--(BUSINESS WIRE)--Kimball Electronics, Inc. (Nasdaq: KE) today announced that it will report third quarter fiscal year 2026 financial results on Tuesday, May 5, 2026, after the closing of the market. The company will host a conference call and live webcast to review the results on Wednesday, May 6, 2026, at 10:00 a.m. Eastern Time. The telephone number to access the conference call is 877-407-8293 / +1 201-689-8349. A live webcast of the conference call can be accessed at investors...

IRVINE, Calif.--(BUSINESS WIRE)--Mobix Labs, Inc. (NASDAQ: MOBX) announced it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement, resolving its prior listing deficiency. Nasdaq confirmed compliance after the Company’s stock traded at or above $1.00 for the required consecutive trading days. Forward-Looking Statements This release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the Company’s Nasdaq listi...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Innovative Transaction & Process UCITS ETF 21.04.2026 LEGR LN IE00BF5DXP42 1,000,002.00 USD 51,364,011.56 51.364  ...